A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer
A Phase II/III Randomized, Open-Label Clinical Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Metastatic Pancreatic Cancer Following Chemotherapy Failure
Sponsor: 1Globe Health Institute LLC
A PHASE2/PHASE3 clinical study on Metastatic Pancreatic Cancer, this trial is actively recruiting participants. The trial is conducted by 1Globe Health Institute LLC and has accumulated 9 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Recruiting PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE2_PHASE3
Status: Unknown Status → Recruiting · Phase: PHASE3 → PHASE2_PHASE3
-
Jan 2022 — May 2024 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
-
Jan 2021 — Jan 2022 [monthly]
Recruiting PHASE3
▶ Show 4 earlier versions
-
Jul 2019 — Jan 2021 [monthly]
Recruiting PHASE3
-
Feb 2019 — Jul 2019 [monthly]
Recruiting PHASE3
-
Dec 2018 — Feb 2019 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Nov 2018 — Dec 2018 [monthly]
Not Yet Recruiting PHASE3
First recorded
Oct 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- 1Globe Health Institute LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barcelona, Spain , Beijing, China , Bourgogne, France , Brest, France , Changchun, China , Changsha, China , Dalian, China , Fuzhou, China , Guangzhou, China , Hangzhou, China and 14 more locations